Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis

(2018) Bing Cao et al.   DIABETES OBESITY & METABOLISM

Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial

(2018) Matthew P. Gilbert et al.   ANNALS OF INTERNAL MEDICINE

Intranasal Insulin Administration Dose-Dependently Modulates Verbal Memory and Plasma Amyloid-β in Memory-Impaired Older Adults

(2017) Mark A. Reger et al.   JOURNAL OF ALZHEIMERS DISEASE

Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced alzheimer disease mouse model

(2016) Liqin Qi et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial

(2016) Michael Gejl et al.   Frontiers in Aging Neuroscience

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics

(2015) Lisbeth V. Jacobsen et al.   CLINICAL PHARMACOKINETICS

Alzheimer’s disease drug-development pipeline: few candidates, frequent failures

(2014) Jeffrey L Cummings et al.   Alzheimers Research & Therapy

Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer’s disease clinical trials

(2012) Jesse M. Cedarbaum et al.   Alzheimers & Dementia

Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study

(2012) M. Nauck et al.   DIABETES OBESITY & METABOLISM

Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline

(2012) Konrad Talbot et al.   JOURNAL OF CLINICAL INVESTIGATION

The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

(2011) P. L. McClean et al.   JOURNAL OF NEUROSCIENCE

Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain

(2011) A. Hamilton et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Insulin metabolism and the risk of Alzheimer disease: The Rotterdam Study

(2010) E. M. C. Schrijvers et al.   NEUROLOGY

The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies

(2009) L. Blonde et al.   DIABETES OBESITY & METABOLISM

Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI

(2009) Susan M. Landau et al.   NEUROBIOLOGY OF AGING

Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system

(2009) Alison Hamilton et al.   NEUROREPORT

A profile of impaired insulin degradation in relation to late-life cognitive decline: A preliminary investigation

(2008) Olivia I. Okereke et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling

(2008) Aileen M. Moloney et al.   NEUROBIOLOGY OF AGING